🇺🇸 FDA
Pipeline program

Tesaglitazar 0.5 or 1 mg

D6160C00032

Phase 3 small_molecule terminated

Quick answer

Tesaglitazar 0.5 or 1 mg for Type 2 Diabetes is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Type 2 Diabetes
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials